Topics

FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial

07:05 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial. The prospective, multi-center, t...

Other Sources for this Article

Tom Langford
Director, Communications and Public Relations
978-882-8408
tlangford@abiomed.com

Ingrid Goldberg Ward
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial"

Quick Search

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...